In Canada, switching to a one-dose, gender-neutral vaccination program for human papillomavirus (HPV) could use vaccine doses more efficiently and prevent a similar number of cervical cancer cases, ...

Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure.

CEPI has approved the advancement of the vaccine program following promising proof-of-concept results generated by Vaxxas in preclinical models, showing excellent thermostability and effective ...

The vaccine against human papillomavirus, or HPV, has reduced cervical cancer by nearly 90% in women vaccinated as ...

Screening for cervical cancer every 15 to 25 years was cost-effective for women vaccinated against HPV between the ages of 12 and 24 years.

COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new ...

Evaxion A/S has announced the initiation of a new vaccine program, EVX-B4, targeting Group A Streptococcus (GAS), a pathogen responsible for a wide range of infections globally, including severe ...